Friday, August 3, 2018

The Case for the 4-Day Workweek

Given the number of workers today who are struggling to achieve a good work-life balance, it pays for companies to explore the merits of offering more flexible arrangements. One company in New Zealand, in fact, did just that, and it was a resounding success.

Perpetual Guardian, a company that offers estate planning services, conducted an experiment wherein it condensed its workweek into only four days for a two-month period. During that time, employees were still paid for a standard five-day workweek but weren't required to show up that extra day.

The result? The company reported that its workers were more focused and productive, spending less time on non-work activity since, presumably, they were afforded more opportunity to tend to personal matters. Employees also reported a better work-life balance and lower stress levels across the board. Perpetual Guardian now wants to make its four-day workweek a permanent fixture -- something its employees will no doubt come to celebrate.

Calendar sitting on wooden surface

IMAGE SOURCE: GETTY IMAGES.

Of course, requiring employees to report to the office only four days a week doesn't work for all businesses. But if yours can make it work, there's a host of benefits to be gained.

Why try a four-day workweek?

Americans aren't strangers to hard work, with 40% of U.S. employees clocking in more than 50 hours a week on a regular basis. But being perpetually chained to a desk can quickly contribute to employee burnout, and when that happens, productivity suffers. Not only that, but research from Stanford University tells us that once employees work more than 50 hours in a given week, their productivity takes a notable dip, regardless of whether they're happy on the job or not. It therefore stands to reason that easing up on the attendance requirement might result in better output, as Perpetual Guardian found.

Remember, the more hours employees are forced to work, the more time they're likely to waste. According to data from OfficeTeam, the average office worker spends about five hours a week doing non-work activities on his or her phone, from answering personal emails to shopping online. By compressing the workweek into four days, you may come to find that employees are less likely to slack off or engage in non-work activities, and instead focus on tackling key tasks.

And then there's your employees' outlook to take into account. When workers feel they're being treated with respect, they tend to reward their employers in the form of harder work and more flexibility on their part. For example, if your company tends to experience after-hour emergencies, your staff members will be more likely to jump in and help on those occasions if they feel they're being well taken care of.

Implementing a four-day workweek also might result in better employee retention. And as we all know, it takes a lot of time and costs a lot of money to replace workers who leave.

Is a four-day workweek suitable for everyone? Absolutely not. But if you think it might work at your company, you have little to lose by giving it a try.

Wednesday, August 1, 2018

Top 5 Biotech Stocks To Watch Right Now

tags:AMGN,ALNY,ARQL,BIIB,

Protalix BioTherapeutics (NYSE:PLX) is a clinical/commercial biotech company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx platform. More details about the company can be found in my December 28, 2016, article, "Protalix BioTherapeutics Receives $24M Order, Is Well Funded, And Has Significant Upside."

On May 1, 2012, Protalix and its partner Pfizer (NYSE:PFE) announced that the FDA approved ELELYSO (taliglucerase alfa) for injection. This is an enzyme replacement therapy (ERT) for the long-term treatment of adults with a confirmed diagnosis of type 1 Gaucher disease. This was the first FDA-approved plant cell-expressed drug derived from Protalix's proprietary manufacturing system ProCellEx.

David Aviezer, Ph.D., MBA, the then president and CEO of Protalix commented:

"We believe that this great news is a recognition of our technology, which is a plant cell manufacturing system from Protalix. This technology is the production process behind taliglucerase alfa and other plant-based Protalix product candidates using our ProCellEx, proprietary manufacturing system."

Top 5 Biotech Stocks To Watch Right Now: Amgen Inc.(AMGN)

Advisors' Opinion:
  • [By Joseph Griffin]

    Field & Main Bank grew its stake in shares of Amgen (NASDAQ:AMGN) by 9.1% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,153 shares of the medical research company’s stock after buying an additional 345 shares during the quarter. Field & Main Bank’s holdings in Amgen were worth $708,000 at the end of the most recent quarter.

  • [By ]

    This week we get our first look at quarterly numbers from major drug and biotech giants such as AbbVie (ABBV)  , Amgen (AMGN)  , Biogen (BIIB) , Biomarin Pharmaceuticals (BMRN)  and Action Alerts PLUS holding Eli Lilly (LLY) , which all provide the market a glimpse of how the first quarter was for the industry over the next few days," according to Real Money Pro columnist Bret Jensen.

  • [By Cory Renauer]

    The recent surge in biotech investment is terrific for the pace of innovation, but that capital isn't heading toward the industry's bigger older players, a couple of which are looking mighty underappreciated right now. Perhaps the investment community's intense focus on start-ups has created interesting opportunities to snap up shares of these two overlooked biotechs at a very nice price.

    Company (Symbol) Forward P/E Ratio Free Cash Flow, Past 12 Months Cash, Cash Equivalents, and Short-Term Investments as of March 31 AbbVie Inc. (NYSE:ABBV) 12.2 $10.0 billion $9.5 billion Amgen, Inc. (NASDAQ:AMGN) 14.2 $10.9 billion $32.2 billion

    Data source: Yahoo! Finance.

  • [By Jon C. Ogg]

    In September of 2016, Amgen Inc. (NASDAQ: AMGN) announced that the FDA had approved its Amjevita as a biosimilar to Humira for multiple inflammatory diseases that included RA and several other related inflammatory diseases.

Top 5 Biotech Stocks To Watch Right Now: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors' Opinion:
  • [By Logan Wallace]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Although Alnylam has a broad and promising pipeline, we note that most candidates are in mid stages of development. These candidates still have a long way to go before hitting the market. The company relies highly on collaborators for funding. Any development/regulatory setback would be a negative for the company.  However, Alnylam reported positive data from the ATLAS study in the first quarter which led to regulatory filings for its late-stage pipeline candidate patisiran and the FDA set an action date of Aug 11, 2018. The company along with its partners Sanofi and The Medicines Company, restarted fitusiran's ATLAS phase III study and advanced inclisiran in the ORION-9, -10, and -11 phase III studies, respectively, with results expected for both programs in 2019. Alnylam expects to achieve the profile of three marketed products by the end of 2020.”

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Keith Speights]

    Speaking of competition, Ionis should have its hands full battling rivals for Tegsedi assuming the drug wins approval. Alnylam (NASDAQ:ALNY) anticipates winning FDA approval for its hATTR drug patisiran within a few weeks. Because the FDA delayed its decision on Tegsedi, Alnylam appears to be in position to reach the market first. In addition to its first-mover advantage, patisiran�appears to have an edge over Tegsedi in efficacy and safety based on clinical data for the two drugs.�

  • [By Sean Williams, Chuck Saletta, and Brian Feroldi]

    So, which biotech stocks should you consider buying in June? That's a question we posed to three of our healthcare-focused investors. Interestingly enough, mid-cap biotech stocks are the clear flavor of the month. If biotech is on your radar in June, our investors suggest you consider Ionis Pharmaceuticals (NASDAQ:IONS), Spark Therapeutics (NASDAQ:ONCE), and Alnylam Pharmaceuticals (NASDAQ:ALNY).

Top 5 Biotech Stocks To Watch Right Now: ArQule Inc.(ARQL)

Advisors' Opinion:
  • [By Lisa Levin] Gainers Foot Locker, Inc. (NYSE: FL) rose 15.3 percent to $53.50 in pre-market trading after the company reported better-than-expected results for its first quarter. Evofem Biosciences, Inc. (NASDAQ: EVFM) rose 10.4 percent to $4.58 in pre-market trading. Evofem Biosciences reported closing of public offering of common stock and warrants. Resonant Inc. (NASDAQ: RESN) rose 7.3 percent to $4.88 in pre-market trading after declining 1.94 percent on Thursday. SolarEdge Technologies, Inc. (NASDAQ: SEDG) shares rose 5.7 percent to $59.65 in pre-market trading after falling 8.43 percent on Thursday. Yirendai Ltd. (NYSE: YRD) rose 5 percent to $30.00 in pre-market trading after reporting Q1 results. Deckers Outdoor Corp (NYSE: DECK) rose 4.9 percent to $108.75 in pre-market trading after reporteingd better-than-expected results for its fiscal fourth quarter. Blue Apron Holdings, Inc. (NYSE: APRN) rose 4.2 percent to $3.21 in pre-market trading after gaining 3.70 percent on Thursday. Recro Pharma, Inc. (NASDAQ: REPH) rose 4 percent to $5.85 in pre-market trading after dropping 54.67 percent on Thursday. ArQule, Inc. (NASDAQ: ARQL) rose 3.8 percent to $4.70 in pre-market trading after gaining 4.86 percent on Thursday. Babcock & Wilcox Enterprises, Inc. (NYSE: BW) shares rose 2.9 percent to $2.85 in pre-market trading after climbing 7.78 percent on Thursday. Bilibili Inc. (NASDAQ: BILI) shares rose 2.5 percent to $14.20 in pre-market trading after surging 11.33 percent on Thursday.

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

  • [By Joseph Griffin]

    ValuEngine upgraded shares of ArQule (NASDAQ:ARQL) from a buy rating to a strong-buy rating in a research report released on Tuesday.

    Several other equities analysts have also issued reports on ARQL. Zacks Investment Research upgraded ArQule from a hold rating to a buy rating and set a $2.50 price objective for the company in a research report on Tuesday, March 20th. BidaskClub upgraded ArQule from a buy rating to a strong-buy rating in a research report on Saturday, March 24th. B. Riley set a $4.00 price objective on ArQule and gave the company a buy rating in a research report on Monday, March 26th. Leerink Swann upgraded ArQule from a market perform rating to an outperform rating in a research report on Thursday, April 5th. Finally, Roth Capital boosted their price objective on ArQule from $5.00 to $6.00 and gave the company a buy rating in a research report on Tuesday, April 17th. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and two have issued a strong buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $5.35.

  • [By Joseph Griffin]

    ArQule (NASDAQ:ARQL)‘s stock had its “buy” rating restated by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Tuesday, Marketbeat Ratings reports. They currently have a $6.00 price target on the biotechnology company’s stock, up from their prior price target of $5.00. Needham & Company LLC’s price target suggests a potential upside of 134.38% from the company’s previous close.

  • [By Cory Renauer]

    What's behind these dramatic gains? Read on to find out.

    Company Gain in H1 2018 Market Cap Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) 270% $1.19 billion ArQule, Inc. (NASDAQ:ARQL) 235% $482 million Endocyte, Inc. (NASDAQ:ECYT) 222% $959 million Madrigal Pharmaceuticals, Inc.�(NASDAQ:MDGL) 205% $3.99 billion

    Data source: YCharts.

  • [By Logan Wallace]

    BidaskClub upgraded shares of ArQule (NASDAQ:ARQL) from a hold rating to a buy rating in a report released on Saturday.

    A number of other research firms have also issued reports on ARQL. Roth Capital upped their price target on ArQule from $5.00 to $6.00 and gave the company a buy rating in a research report on Tuesday, April 17th. Leerink Swann upgraded ArQule from a market perform rating to an outperform rating in a research report on Thursday, April 5th. Zacks Investment Research lowered ArQule from a buy rating to a hold rating in a research report on Wednesday, April 4th. ValuEngine upgraded ArQule from a hold rating to a buy rating in a research report on Wednesday, May 2nd. Finally, B. Riley set a $4.00 price target on ArQule and gave the company a buy rating in a research report on Monday, March 26th. Seven analysts have rated the stock with a buy rating, The stock currently has an average rating of Buy and an average target price of $4.69.

  • [By Joseph Griffin]

    Shares of ArQule, Inc. (NASDAQ:ARQL) were down 5.4% during trading on Wednesday . The company traded as low as $4.71 and last traded at $4.73. Approximately 3,358,864 shares traded hands during trading, an increase of 289% from the average daily volume of 863,008 shares. The stock had previously closed at $5.00.

Top 5 Biotech Stocks To Watch Right Now: Biogen Idec Inc(BIIB)

Advisors' Opinion:
  • [By Chris Lange]

    Biogen Inc. (NASDAQ: BIIB) shares jumped early on Friday after the firm, in conjunction with Eisai out of Japan, announced positive results from a midstage Alzheimer��s study. The topline results came from the Phase 2 study with BAN2401, an anti-amyloid beta protofibril antibody, in 856 patients with early Alzheimer’s disease.

  • [By Brian Feroldi]

    Data source: Alkermes. GAAP = generally accepted accounting principles.

    What happened with Alkermes this quarter? Sales of Alkermes'�opioid- and alcohol-abuse prevention drug Vivitrol grew 7% to $62.7 million. Sales of the company's�schizophrenia drug�Aristada�rose 62% to $29.2 million. Manufacturing and royalty revenue related to�Johnson & Johnson's schizophrenia drugs jumped 15% to $68.8 million. Manufacturing and royalty revenue related to�Acorda Therapeutics' multiple sclerosis drug�fell�3% to $28.3 million. Research and development revenue earned as part of its collaboration with�Biogen (NASDAQ:BIIB) for BIIB098 -- which used to be called ALKS 8700 -- was $17.5 million.

    Looking beyond the financials, here's an overview of the key events from the period:

  • [By Cory Renauer]

    Biotech traders get heaps of attention, but buying promising young drugmakers and holding them for the long term is a far easier way to get rich. Case in point: Spreading $10,000 evenly among shares of Biogen Inc. (NASDAQ:BIIB),�Celgene Corporation (NASDAQ:CELG), and�Gilead Sciences Inc.�(NASDAQ:GILD) around this time in 1998 would have made you a millionaire already.�

  • [By Keith Speights]

    This has been a bad year for Biogen (NASDAQ:BIIB) so far -- the biotech's stock has dropped more than 10% since it began. But 2018 has been horrible for Acadia Pharmaceuticals (NASDAQ:ACAD), which has seen its share price plunge nearly 40%.

  • [By Brian Orelli]

    Data source: Ionis Pharmaceuticals.

    What happened with Ionis Pharmaceuticals this quarter? Revenue increased thanks to $41 million in royalties from Biogen's (NASDAQ:BIIB) sales of Spinraza, up from just $5 million in the year-ago quarter. Because the tiered royalty rates reset each year, the royalties as a percentage of sales will end up being higher in the quarters to come this year. Despite the higher revenue, earnings turned negative on a GAAP (generally accepted accounting principles) basis: Ionis and Akcea Therapeutics (NASDAQ:AKCA) increased spending in preparation for the launch of Tegsedi for hereditary transthyretin amyloidosis (hATTR), and Waylivra for familial chylomicronemia syndrome, a rare disease that causes the buildup of lipids. Ionis is still the majority owner of Akcea, so its financials are incorporated into Ionis' financials. The Food and Drug Administration pushed back its goal for making a decision on the marketing application for Tegsedi (the new brand name for inotersen) to Oct. 6, 2018. Ionis provided additional data analysis that the FDA needs additional time to review. In April, Ionis signed another deal with Biogen to develop antisense drugs for neurological disorders. In the deal, Ionis gets $1 billion up front, including an equity investment, in exchange for Biogen having first choice of neurology targets on which to exclusively collaborate with Ionis. Biogen is paying for everything beyond the initial discovery stage, with Ionis eligible for royalties and milestone payments as the drugs advance.

    Image source: Getty Images.

  • [By Chris Lange]

    Biogen Inc.’s (NASDAQ: BIIB) second-quarter report is scheduled for Tuesday before the markets open. The consensus estimates are $5.24 in earnings per share (EPS) on $3.26 billion in revenue. The shares ended the week trading at $357.56. The consensus price target is $367.08, and the 52-week trading range is $249.17 to $370.57.